✦ LIBER ✦

714 PAIN AND QUALITY OF LIFE (QOL) ANALYSES FROM THE PHASE 3 RANDOMIZED ALSYMPCA STUDY WITH RADIUM-223 DICHLORIDE (RA-223) IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS WITH BONE METASTASES

✍ Scribed by Tomblyn, Michael; Nilsson, Sten; Vogelzang, Nicholas; Sartor, A. Oliver; Cislo, Paul; Van Gool, Renilt; Aksnes, Anne-Kirsti; Parker, Chris

Book ID: 123002075
Publisher: Lippincott Williams and Wilkins
Year: 2013
Tongue: English
Weight: 50 KB
Volume: 189
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2013.02.273

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P124 Long-term safety of radium-223 dich

P124 Long-term safety of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study

✍ Nilsson, S; Schrader, A.J.; Kliment, J.; Solberg, A.; Franzén, L.; Bottomley, D. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 66 KB

101 Updated analysis of radium-223 dichl

101 Updated analysis of radium-223 dichloride (Ra-223) impact on pain, skeletal-related events (SRE), and survival from the phase 3 randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) and bone metastases

✍ Heinrich, D.; Helle, S.I.; Chodacki, A.; Wiechno, P.; Garcia-Vargas, J.; Staudac 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 110 KB

Radium-223 Dichloride (Ra-223) Impact on

Radium-223 Dichloride (Ra-223) Impact on Skeletal-Related Events, External Beam Radiation Therapy (EBRT), and Pain in Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases: Updated Results From the Phase 3 ALSYMPCA Trial

✍ Michalski, J.; Sartor, O.; Parker, C.; Shan, M.; Garcia-Vargas, J.; Aksnes, A.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 64 KB

865 Effects of radium-223 dichloride (Ra

865 Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA trial

✍ Heinrich, D.; Parker, C.; Shan, M.; Wilhelm, S.; Garcia-Vargas, J.; O'Bryan-Tear 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Estimating the Economic Impact of Radium

Estimating the Economic Impact of Radium Ra 223 Dichloride (Radium-223) in Treatment of Castration-Resistant Prostate Cancer (CRPC) with Symptomatic Bone Metastases and No Known Visceral Metastatic Disease

✍ Valderrama, A.; Bilir, S.P.; Wehler, E.A.; Seal, B.S.; Wen, L.; Yaldo, A.; Munak 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

Overall Survival Benefit of Radium-223 C

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

✍ C. Parker; D. Heinrich; J.M. O'Sullivan; S. Fossa; A. Chodacki; T. Demkow; A. Cr 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB